Evidence map›Paper›PMID 41584352›Full record

ReviewActa pharmaceutica Sinica. B2026

Unraveling the FGFR-RNA splicing axis: Mechanisms, oncogenic crosstalks and innovations for therapeutic purpose.

Xuquan Xian, Ruyi Gong, Shunzi Rong, Zhihao Zhang, Fengtong Jia, Lin Li, Zhengguo Chen, Beatrice Eymin, Tao Jia

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xuquan XianNational Health Commission (NHC) Key Laboratory of Nuclear Technology Medical Transformation, Sichuan Provincial Engineering Research Center of Nuclear Medical Equipment Translation and Application, Sichuan Clinical Research Center for Radiation and Therapy, Mianyang Central Hospital, Mianyang 621000, China.
Ruyi GongKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
Shunzi RongKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
Zhihao ZhangKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
Fengtong JiaKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
Lin LiNational Health Commission (NHC) Key Laboratory of Nuclear Technology Medical Transformation, Sichuan Provincial Engineering Research Center of Nuclear Medical Equipment Translation and Application, Sichuan Clinical Research Center for Radiation and Therapy, Mianyang Central Hospital, Mianyang 621000, China.
Zhengguo ChenNational Health Commission (NHC) Key Laboratory of Nuclear Technology Medical Transformation, Sichuan Provincial Engineering Research Center of Nuclear Medical Equipment Translation and Application, Sichuan Clinical Research Center for Radiation and Therapy, Mianyang Central Hospital, Mianyang 621000, China.
Beatrice EyminUniversity Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Team RNA Splicing, Cell Signaling and Response to Therapies, Institute For Advanced Biosciences, Grenoble 38000, France.
Tao JiaNational Health Commission (NHC) Key Laboratory of Nuclear Technology Medical Transformation, Sichuan Provincial Engineering Research Center of Nuclear Medical Equipment Translation and Application, Sichuan Clinical Research Center for Radiation and Therapy, Mianyang Central Hospital, Mianyang 621000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibroblast growth factor receptor (FGFR) signaling is a pivotal regulator of tumor progression, driving cell proliferation, survival, metastasis, and therapeutic resistance across diverse cancer types. RNA alternative splicing profoundly shapes FGFR isoform diversity, endowing tumors with heterogeneity and adaptability to targeted interventions. While significant progress has been made in identifying splicing regulators that govern FGFR pre-mRNA processing, the extracellular cues influencing this process and the reciprocal impact of FGFR signaling pathway on global splicing networks remain underexplored. This review provides a comprehensive overview of the bidirectional interplay linking FGFR signaling and RNA splicing in cancer. Mechanistically, we first detail how

Indexed as

Biomarker discoveryFGF–FGFRIsoform diversityPrecision oncologyRadiotheranosticsRNA splicingTherapeutic resistanceTumorigenesis

Identifiers

PMID41584352
PMCPMC12828087

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.